Dec 13, 2019: Shares of Amarin Corp. jumped 5% on the extended trading session after the company said, it received approval to market its drug Vascepa for. U.S. Food and Drug Administration has approved Amarin’s new indication and label expansion for Vascepa capsules.
Now, it is the first and only drug approved by the FDA as an addition to maximally tolerated statin therapy in order to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with the elevated triglyceride levels and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for the cardiovascular disease. https://fda.einnews.com/article/504835618?lcf=8DWPqPuUsDVNDakfEIxsCA%3D%3D
